Upstream Bio Announces Phase 3 Plans for Verekitug in Severe Asthma, CRSwNP

What Happened

• On September 1, 2026 Upstream Bio announced pivotal Phase 3 development plans for its candidate verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company issued a press release and disclosed the program details in an 8-K (Regulation FD disclosure and Other Events).
• Upstream Bio said it remains on track to initiate the Phase 3 trials in the first quarter of 2027 and, with supportive Phase 3 results, could submit Biologics License Applications (BLAs) to the FDA and potentially launch verekitug as early as 2030.

Key Details

• Dosing: single high-dose subcutaneous regimen of 400 mg every 12 weeks.
• Trial design: one placebo-controlled study per indication; approximately 1,500 patients total across both trials.
• Populations: broad eligibility with no restriction based on baseline biomarkers.
• Primary endpoints: asthma — annualized asthma exacerbation rate over 48 weeks; CRSwNP — co-primary endpoints of change from baseline in nasal polyp score and nasal congestion score at 48 weeks.

Why It Matters

• These are pivotal (Phase 3) programs, so successful trials would be the main path to regulatory approval and commercial launch. The 400 mg every-12-weeks regimen and broad enrollment could affect market positioning and patient convenience if approved.
• The planned timelines (start in Q1 2027; potential launch as early as 2030 with supportive results) set investor expectations for key clinical and regulatory milestones, but the company also disclosed standard forward-looking risk factors (trial outcomes, funding, manufacturing, FDA interactions, and other risks). Investors should monitor trial initiation, enrollment progress, data readouts, and any regulatory feedback.